Recently, the non-steroidal mineralocorticoid receptor agonist finerenone, which had already been shown to reduce the risk of cardiorenal outcomes in patients with T2D, demonstrated a benefit on HF-related outcomes in patients with HFmrEF and HFpEF [11, 38]. This evidence concerns the gene NR3C2 and type 2 diabetes mellitus.